Follow us on Facebook!
Follow us on Twitter!
Follow us on Youtube!

News archive

As part of the Advocate Development Programme (ADP), MPE is organising an online webinar about science in patient advocacy. Although the webinars held within the ADP are usually open only to our ADP trainees, on this occasion we would like to invite to the webinar all our members and patient advocates interested in science. The webinar “Science in patient advocacy” will be given by Bettina Ryll, chair of the ESMO Patient Advocates Working Group (PAWG) and founder of the Melanoma Patient Network Europe (MPNE).

Continue reading

The 59th American Society of Hematology (ASH) Annual Meeting will take place from 9 – 12 December in Atlanta, Georgia, United States (US). Myeloma Patients Europe (MPE) will be attending the meeting, alongside thousands of leading doctors, researchers and patient advocates in the field of blood cancer (hematology). Below we explain ASH and the importance of the meeting to patient advocates.


Continue reading

Melphalan (Alkeran®), a chemotherapy drug commonly used in myeloma, was not available in several European countries towards the end of 2016. Myeloma Patients Europe (MPE) became aware of the situation following reports from our members that it was impacting negatively on myeloma patients in their countries. We conducted a survey to explore the issue further, the results of which you can see here.

Continue reading

Lugano/Brussels, 3 August 2017. Three leading European organisations in the fight against cancer have called the European Union (EU) to urgently increase its support for independent academic research for the benefit of cancer patients, in an article published (today) in ESMO Open.

“Independent academic research is endangered for lack of funds and adequate legislation,” said Rolf A. Stahel, ESMO Past President and co-founder of the CAREFOR platform. “Working closely with EU institutions, we can make sure Europe is equipped with efficient legal framework and a vision to become the best place for research and innovation, for the ultimate benefit of cancer patients,” he stated. Continue reading

It is with great sadness that we share with you that our friend and colleague, Jelle Palsma passed away.

Jelle was part of the board of MPE’s French member, Association Française des Malades du Myélome Multiple (AF3M), and was a very active representative at MPE. Despite his health condition, Jelle was involved in highly relevant MPE initiatives with a remarkable positive attitude. Continue reading

The most important Haematology scientific meeting in Europe, the European Hematology Association (EHA) Annual Meeting was held between 22 and 25 June 2017 in Madrid (Spain). Continue reading

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)

WhatsApp Image 2017-06-04 at 22.27.44CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of myeloma upon receiving a new type of immunotherapy  ̶  chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. The study was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

“Although recent advances in chemotherapy have prolonged life expectancy in multiple myeloma, this cancer remains incurable,” said study author Wanhong Zhao, MD, PhD, an associate director of hematology at The Second Affiliated Hospital of Xi’an Jiaotong University in Xi’an, China. “It appears that with this novel immunotherapy there may be a chance for cure in multiple myeloma, but we will need to follow patients much longer to confirm that.”   Continue reading

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)

Chicago – According to Phase 3 ‘482 study, the largest international multiple myeloma trial ever conducted with 1,718 patients involved, patients who receive denosumab (XGEVA) had a significantly lower rate of renal adverse events compared to zoledronic acid (10.0 percent versus 17.1 percent, p<0.001). The study met its primary endpoint, demonstrating denosumab is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p=0.01). ). These results was presented yesterday at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Continue reading

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)

June, 2, 2017

ASCO_gradientCHICAGO – About 50% of all cancer survivors report moderate to high fear of recurrence. The fear can be so distressing that it negatively affects medical follow-up behavior, mood, relationships, work, goal setting, and quality of life, according to a study presented during the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. Yet, interventions to alleviate this fear are lacking. Continue reading

yacob_bnWe all were saddened to hear of our recent loss of Yacob Yacobovitch, who passed away on the 18th of april 2017. Yacob Yacobovitch was member of Myeloma Patients Europe from 2012 until 2016. Continue reading